摘要
目的:系统评价川芎嗪治疗特发性肺纤维化(Idiopathic Pulmonary Fibrosis,IPF)的临床疗效。方法:系统检索川芎嗪治疗IPF的随机对照试验(Randomized Controlled Trial,RCT)文献,检索时间截至2015年3月,研究者按照纳入和排除标准独立筛选文献、提取资料和按照Cochrane系统评价手册推荐方法学评价文献质量后,采用Rev Man 5.3软件进行Meta分析。结果:最后纳入7项RCT研究,388例患者,试验组207例,对照组181例。Meta分析显示:在改善临床总有效率方面RR=1.22,95%CI[1.08,1.39],结果有统计学意义(P=0.002);在提高Pa O2方面MD=6.20,95%CI[0.45,11.95],结果具有统计学意义(P=0.03)。未见不良反应。结论:川芎嗪用于治疗IPF可能具有一定的疗效,但是安全性尚不明确,仍需进行大样本、多中心、高质量的临床RCT进一步验证。
Objective： To systematically assess clinical efficacy of Ligustrazine treating Idiopathic Pulmonary Fibrosis. Methods：Randomized controlled trials of Ligustrazine treating Idiopathic Pulmonary Fibrosis were selected with the deadline for March2015. The researchers extract information according to inclusion and exclusion criteria and the risk of bias of included trials was assessed according to criteria recommended by Cochrane handbook for systematic reviews of interventions. Statistical analyses were performed by Review Manager 5. 3 software. Results： 7 qualified trials involving 388 participants were included. Meta-analysis indicated that Ligustrazine can improve treatment rate（ RR = 1. 22,95% CI[1. 08,1. 39 ]） and level of Pa O2（ MD = 6. 20,95% CI[0. 45,11. 95]）. Conclusion： Current evidence indicates that Ligustrazine may have certain curative effects in treating IPF,but security is not yet clear,however,we still need a large sample,multi-center,high quality clinical RCT.
出处
《世界中医药》
CAS
2016年第1期163-168,共6页
World Chinese Medicine
基金
国家自然科学基金面上项目(编号:81173390)
